With the recruitment of Esbjörn Melin, CombiGene further strengthens the company’s scientific position

Mar 2, 2021

CombiGene’s epilepsy project CG01 is in late preclinical phase and the company is currently intensifying preparations for the clinical program, where the Phase I study is scheduled to begin in 2022. For the clinical program, CombiGene will use GMP-produced material and for the later phases a more advanced method is needed to analyze the biological activity. As the development of such an analytical method takes a relatively long time, the UK Medicines Agency (MHRA) at the last advisory meeting recommended that CombiGene start this work as soon as possible. CombiGene has therefore recruited Esbjörn Melin to the position of industrial post-doc so that this work begins immediately.

Esbjörn Melin has been a PhD student with Professor Merab Kokaia, one of CombiGene’s scientific founders, and in the autumn of 2020 received his PhD with the dissertation Advancing gene therapy for epilepsy. Translational pre-clinical studies with neuropeptide Y and glial cell-line derived neurotrophic factor. Esbjörn thus has deep knowledge of CombiGene’s epilepsy project and was, among other things, responsible for the practical execution of the chronic study with CG01 that was conducted in collaboration between Professor Kokaia and Associate Professor David Woldbye, CombiGene’s other scientific founder.

Esbjörn will be responsible for the development of an analytical method to measure the biological activity of CG01 and in parallel with this also conduct other studies to establish further evidence around neuropeptide Y and its receptor Y2, the two active substances encoded in CG01. “I am very pleased with the recruitment of Esbjörn Melin”, says Karin Agerman, CombiGene’s Chief Research & Development Officer. “Through his research, he has built up a deep scientific understanding of epilepsy and CG01’s mechanism of action and will thus contribute to the development of CG01 and further strengthen the company’s scientific position.”


CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.



CombiGene AB, Agavägen 52A, SE-181 55 Lidingö


Linked In     Twitter      Facebook